doripenem has been researched along with colistin in 28 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (3.57) | 29.6817 |
2010's | 24 (85.71) | 24.3611 |
2020's | 3 (10.71) | 2.80 |
Authors | Studies |
---|---|
Giamarellou, H; Kanellakopoulou, K | 1 |
Cacciarelli, TV; Muder, RR; Shields, RK; Singh, N; Sun, HY | 1 |
Bergen, PJ; Bulitta, JB; Forrest, A; Jacob, J; Li, J; Nation, RL; Paterson, DL; Sidjabat, HE; Tsuji, BT | 1 |
Apisarnthanarak, A; Mundy, LM | 1 |
Clancy, CJ; Jernigan, MG; Nguyen, MH; Press, EG; Shields, RK | 1 |
Bergen, PJ; Bulitta, JB; Davis, K; Deris, ZZ; Forrest, A; Jacob, J; Ku, CK; Li, J; Nation, RL; Paterson, DL; Poudyal, A; Soon, RL; Tsuji, BT; Velkov, T; Yu, HH | 1 |
Ambe, LA; Casella, LG; Doi, Y; Ernst, RK; O'Hara, JA; Pelletier, MR; Shanks, RM; Townsend, BM | 1 |
Caio, C; Ceccarelli, G; Falcone, M; Giordano, A; Mezzatesta, ML; Stefani, S; Venditti, M | 1 |
Bordi, E; Capone, A; D'Arezzo, S; Di Caro, A; Mazzarelli, A; Petrosillo, N; Principe, L | 1 |
Erdogan-Yildirim, Z; Manafi, M; Sauermann, R; Schwameis, R; Strommer, S; Zeitlinger, MA | 1 |
Chen, L; Cheng, S; Clancy, CJ; Doi, Y; Farrell, AN; Hao, B; Hong, JH; Kreiswirth, BN; Nguyen, MH; Perlin, DS; Shields, RK; Zhao, Y | 1 |
Casari, E; Ferrario, A; Morelli, P; Piazza, A; Tordato, F | 1 |
Clancy, CJ; Doi, Y; Nguyen, MH; O'Hara, JA; Oleksiuk, LM; Press, EG; Shields, RK; Updike, CL | 1 |
Chen, L; Clancy, CJ; Hao, B; Kreiswirth, BN; Nguyen, MH; Perlin, DS; Shields, RK | 1 |
Ariza, J; Bergen, PJ; Li, J; Lora-Tamayo, J; Luo, X; Murillo, O; Nation, RL; Poudyal, A; Yu, HY | 1 |
Bulitta, JB; Cheah, SE; Li, J; Nation, RL | 1 |
Mataraci-Kara, E; Ozbek Celik, B; Yilmaz, M | 1 |
Chen, L; Clancy, CJ; Clarke, LG; Eschenauer, GA; Kreiswirth, BN; Nguyen, MH; Potoski, BA; Press, EG; Shields, RK | 1 |
Adler, B; Aranda, J; Boyce, JD; Crane, B; Deveson Lucas, D; Harper, M; Harrison, P; Henry, R; Li, J; Li, Z; Nation, RL; Powell, D | 1 |
Bergen, PJ; Bulitta, JB; Forrest, A; Holden, PN; Landersdorfer, CB; Li, J; Ly, NS; Nation, RL; Rao, GG; Tsuji, BT | 1 |
Ahmed, SS; Alp, E; Demiraslan, H; Dinc, G; Doganay, M; Elmali, F | 1 |
Choi, IS; Choi, JA; Jang, SJ; Jeong, SH; Kang, SH; Kim, CM; Moon, DS; Park, G; Park, GC | 1 |
Hu, YF; Liu, CP; Shih, SC; Wang, NY | 1 |
Creek, DJ; Forrest, A; Li, J; Maifiah, MH; Nation, RL; Tsuji, BT; Velkov, T | 1 |
Cancelli, F; Castaldi, D; Ciardi, MR; Cipolla, A; D'Abramo, A; D'Agostino, C; Mascellino, MT; Mastroianni, CM; Oliva, A; Russo, G; Scorzolini, L; Vullo, V | 1 |
Fu, L; Li, H; Li, X; Liu, J; Luo, S; Wan, Z; Wang, Y; Wu, X; Xie, X; Zhao, Z | 1 |
Istanbullu Tosun, A; Mataraci Kara, E; Özbek Çelik, B; Yilmaz, M | 1 |
Baccaro, M; Bakker, W; Murali, A; Rietjens, IMCM; van Ravenzwaay, B; Wang, J; Zhang, N; Zheng, W | 1 |
1 review(s) available for doripenem and colistin
Article | Year |
---|---|
Current therapies for pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic | 2008 |
27 other study(ies) available for doripenem and colistin
Article | Year |
---|---|
A novel combination regimen for the treatment of refractory bacteremia due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant recipient.
Topics: Anti-Bacterial Agents; Bacteremia; Bile Duct Diseases; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Liver Transplantation; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2010 |
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Colony Count, Microbial; Cystic Fibrosis; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Half-Life; Humans; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin.
Topics: Carbapenems; Colistin; Cross Infection; Doripenem; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fosfomycin; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Retrospective Studies; Time Factors | 2012 |
The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Combinations; Drug Interactions; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2012 |
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Synergism; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2012 |
Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains.
Topics: Acinetobacter baumannii; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Larva; Lipid A; Microbial Sensitivity Tests; Moths; Signal Transduction; Vancomycin | 2013 |
Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Carbapenems; Colistin; Doripenem; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Pneumonia, Ventilator-Associated; Treatment Outcome | 2013 |
In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Intensive Care Units; Microbial Sensitivity Tests; Minocycline; Tertiary Healthcare; Tigecycline | 2013 |
Effect of pulmonary surfactant on antimicrobial activity in vitro.
Topics: Acetamides; Animals; Anti-Infective Agents; Aza Compounds; Carbapenems; Colistin; Daptomycin; Doripenem; Fluoroquinolones; Linezolid; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Oxazolidinones; Pulmonary Surfactants; Quinolines; Staphylococcus aureus; Swine; Tigecycline | 2013 |
Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Gene Expression; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Multivariate Analysis; Mutation; Porins; Promoter Regions, Genetic | 2013 |
Successful treatment of post-neurosurgical multidrug-resistant Pseudomonas aeruginosa meningo-encephalitis with combination therapy of colistin, rifampicin and doripenem.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Male; Meningoencephalitis; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Surgical Wound Infection; Treatment Outcome | 2014 |
In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Administration Schedule; Drug Combinations; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Sulbactam | 2014 |
Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes.
Topics: Algorithms; Anti-Bacterial Agents; Aspartic Acid; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Therapy, Combination; Genotype; Gentamicins; Glycine; Klebsiella pneumoniae; Microbial Sensitivity Tests; Mutagenesis, Insertional; Porins | 2014 |
Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
Topics: Anti-Bacterial Agents; Biofilms; Carbapenems; Colistin; Colony Count, Microbial; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2014 |
Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Colistin; Colony Count, Microbial; Doripenem; Microbial Sensitivity Tests; Models, Statistical | 2015 |
Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit.
Topics: Carbapenems; Colistin; Doripenem; Dose-Response Relationship, Drug; Drug Combinations; Humans; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Minocycline; Rifampin; Tigecycline; Tobramycin | 2014 |
Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Therapy, Combination; Female; Genotype; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Porins; Retrospective Studies | 2015 |
The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Gene Expression Profiling; Models, Theoretical; Sequence Analysis, RNA; Time Factors | 2015 |
Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Microbial Viability; Models, Theoretical; Pseudomonas aeruginosa; Time Factors | 2015 |
Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Male; Mice; Mice, Inbred BALB C; Minocycline; Sepsis; Sulbactam; Tigecycline | 2015 |
In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Minocycline; Multilocus Sequence Typing; Tigecycline | 2016 |
In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Taiwan; Thienamycins | 2016 |
Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Membrane Lipids; Metabolomics; Signal Transduction | 2017 |
In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Colistin; Doripenem; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2017 |
In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli.
Topics: Acinetobacter baumannii; Administration, Intravenous; Animals; Anti-Bacterial Agents; Biofilms; Colistin; Disease Models, Animal; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; Monte Carlo Method; Sulbactam; Treatment Outcome; Urinary Tract Infections | 2020 |
Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Ceftazidime; Colistin; Doripenem; Drug Combinations; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Real-Time Polymerase Chain Reaction; Tigecycline; Tobramycin | 2020 |
In vitro models to detect in vivo bile acid changes induced by antibiotics.
Topics: Animals; Anti-Bacterial Agents; Bile Acids and Salts; Caco-2 Cells; Colistin; Doripenem; Humans; Meropenem; Rats; RNA, Ribosomal, 16S; Taurocholic Acid; Tobramycin | 2022 |